Sugi Predict

Sugi Predict / Targets / PRMT5

PRMT5

Protein arginine N-methyltransferase 5 · O14744 · PRMT5 on Sugi Atlas →

132,769 patent compounds predicted against PRMT5, 66,163 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL474871 SCHEMBL474871 0.78 18/20
SCHEMBL496566 SCHEMBL496566 0.51 16/20
SCHEMBL474927 SCHEMBL474927 0.49 16/20
SCHEMBL474831 SCHEMBL474831 0.54 15/20
SCHEMBL191943 SCHEMBL191943 0.47 15/20
SCHEMBL496381 SCHEMBL496381 0.56 14/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL495605) 0.55 14/20
SCHEMBL475133 SCHEMBL475133 0.49 14/20
SCHEMBL191900 SCHEMBL191900 0.51 13/20
SCHEMBL475131 SCHEMBL475131 0.51 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL496305) 0.50 12/20
SCHEMBL496318 SCHEMBL496318 0.50 11/20
SCHEMBL496319 SCHEMBL496319 0.50 11/20
SCHEMBL416491 SCHEMBL416491 0.56 10/20
SCHEMBL304374 SCHEMBL304374 0.39 10/20
SCHEMBL304608 SCHEMBL304608 0.38 10/20
SCHEMBL313776 SCHEMBL313776 0.64 9/20
SCHEMBL473465 SCHEMBL473465 0.49 9/20
SCHEMBL59610 SCHEMBL59610 0.71 7/20
SCHEMBL173151 SCHEMBL173151 0.71 7/20

Clinical trials — most relevant to PRMT5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
L-arginine Treatment in Mild Hypertension PHASE4UNKNOWN
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) PHASE3RECRUITING
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial PHASE3COMPLETED
L-Arginine in Pre-Eclampsia PHASE3COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors PHASE1/PHASE2RECRUITING
Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial PHASE2COMPLETED
Nitrite Supplementation in Long COVID Patients PHASE2COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors PHASE1RECRUITING
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors PHASE1COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
iNOS With Positron Emission Tomography (PET) in Cellular Inflammation. EARLY_PHASE1COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure nanENROLLING_BY_INVITATION
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD nanUNKNOWN
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment nanUNKNOWN
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD nanCOMPLETED
Study of the Articular Microbiota in Rheumatoid Arthritis. nanCOMPLETED
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
DNA Methylation and Perioperative Pain Treatment nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Impact of Weight Loss on the Human Sperm Epitranscriptome nanACTIVE_NOT_RECRUITING
Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Diabetes nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
Effect of Arginine and Glutamine on Radiation-induced Oral Mucositis: a Trible Blinded Randomized Controlled Clinical Trial nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRMT5 binder may also engage these)

ProteinNameSimilarity
A7YW45 — 1.000 A7YW45 →
Q5R698 — 1.000 Q5R698 →
Q4R5M3 — 1.000 Q4R5M3 →
Q8CIG8 — 1.000 Q8CIG8 →
Q6YXZ7 — 0.999 Q6YXZ7 →
Q6NUA1 — 0.996 Q6NUA1 →
A2X0Q3 — 0.994 A2X0Q3 →
Q8GWT4 — 0.983 Q8GWT4 →
Q9SRU7 — 0.982 Q9SRU7 →
Q9WU20 — 0.981 Q9WU20 →
Q9V6U8 — 0.979 Q9V6U8 →
O94460 — 0.979 O94460 →
Q5RGJ5 — 0.979 Q5RGJ5 →
Q9SE94 — 0.979 Q9SE94 →
Q0J7N5 — 0.979 Q0J7N5 →
Q641Y5 — 0.979 Q641Y5 →
Q4QQY7 — 0.979 Q4QQY7 →
Q28HC6 — 0.979 Q28HC6 →
Q8AVL0 — 0.979 Q8AVL0 →
P45437 — 0.978 P45437 →
Q6ESI7 — 0.978 Q6ESI7 →
Q7SYK1 — 0.978 Q7SYK1 →
Q60HE5 — 0.978 Q60HE5 →
E7F3I6 — 0.978 E7F3I6 →
Q75HE6 — 0.977 Q75HE6 →
Q8IYB8 — 0.977 Q8IYB8 →
O80585 — 0.977 O80585 →
Q9UIC8 — 0.977 Q9UIC8 →
Q4V7N2 — 0.977 Q4V7N2 →
G6PD Glucose-6-phosphate 1-dehydrogenase 0.977 landscape →